Conclusion of non-exclusive discount agreement for Fentanyl
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Fentanyl (ATC-Code nach WHO: N02AB03)
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
The buyer may terminate the Open-House process early if an exclusive discount agreement is signed. Existing agreements...
No minimum purchase quantities; actual demand depends on prescription behavior and patient numbers, leading to unpredic...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Jan 31, 2028
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jan 2028
- Conclusion of non-exclusive discount agreements for pharmaceutical products with the active substance Fentanyl (ATC N02AB03).
- Limited to sublingual tablets and lozenges.
Show full summary
Non-exclusive pharmaceutical discount agreement (Rabattvereinbarung) under § 130a(8) SGB V for the active substance Fentanyl in sublingual tablet and lozenge dosage forms. The agreement is concluded via an Open-House model, meaning any interested pharmaceutical company meeting the conditions can participate without exclusivity. No minimum purchase quantities are guaranteed. The contract runs until 31 January 2028. Participation is via the DTVP portal with strict confidentiality of tender documents.
Risks
The buyer may terminate the Open-House process early if an exclusive discount agreement is signed. Existing agreements...
No minimum purchase quantities; actual demand depends on prescription behavior and patient numbers, leading to unpredic...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical undertaking within the meaning of § 4(18) AMG for the offered medicinal products.
Eligibility
- Must submit a self-declaration on the absence of exclusion grounds (§§ 123, 124 GWB).
Administrative
- Must submit a self-declaration on compliance with EU sanctions against Russia (Art. 5k of Regulation (EU) 833/2014).
Requirements may be incomplete.
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Conclusion of non-exclusive discount agreement for Fentanyl
Non-exclusive discount agreement for Fentanyl (ATC N02AB03) in sublingual tablet and lozenge forms under an Open-House model. No individual negotiations, no exclusivity, no minimum volume guarantee. Contract end date: 31 January 2028.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Fentanyl (ATC-Code nach WHO: N02AB03)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 07 Apr 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 240015-2026
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
The buyer may terminate the Open-House process early if an exclusive discount agreement is signed. Existing agreements...
No minimum purchase quantities; actual demand depends on prescription behavior and patient numbers, leading to unpredic...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications